[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE526041T1 - Verfahren zur hemmung okularer vorgänge - Google Patents

Verfahren zur hemmung okularer vorgänge

Info

Publication number
ATE526041T1
ATE526041T1 AT02804786T AT02804786T ATE526041T1 AT E526041 T1 ATE526041 T1 AT E526041T1 AT 02804786 T AT02804786 T AT 02804786T AT 02804786 T AT02804786 T AT 02804786T AT E526041 T1 ATE526041 T1 AT E526041T1
Authority
AT
Austria
Prior art keywords
inhibiting
methods
occular
processes
agents
Prior art date
Application number
AT02804786T
Other languages
English (en)
Inventor
David Hinton
Shikun He
Noelynn Oliver
Original Assignee
Fibrogen Inc
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc, Univ Southern California filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE526041T1 publication Critical patent/ATE526041T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Surgery (AREA)
AT02804786T 2001-12-11 2002-12-11 Verfahren zur hemmung okularer vorgänge ATE526041T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33954701P 2001-12-11 2001-12-11
PCT/US2002/039777 WO2003049773A1 (en) 2001-12-11 2002-12-11 Methods for inhibiting ocular processes

Publications (1)

Publication Number Publication Date
ATE526041T1 true ATE526041T1 (de) 2011-10-15

Family

ID=23329537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804786T ATE526041T1 (de) 2001-12-11 2002-12-11 Verfahren zur hemmung okularer vorgänge

Country Status (8)

Country Link
US (1) US20030153524A1 (de)
EP (1) EP1463531B1 (de)
JP (1) JP2005519881A (de)
CN (1) CN1602207A (de)
AT (1) ATE526041T1 (de)
AU (1) AU2002366641A1 (de)
HK (1) HK1069767A1 (de)
WO (1) WO2003049773A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2482789A1 (en) * 2002-04-30 2003-11-13 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treatglaucomatous retinopathies/optic neuropathies
US20040116409A1 (en) * 2002-11-08 2004-06-17 Campochiaro Peter A Ocular therapy
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP4248751A3 (de) * 2004-01-23 2023-11-01 President and Fellows of Harvard College Verbesserte vorgangsweise für die behandlung von degenerativen erkrankungen der retina
DE602005008013D1 (de) * 2004-02-11 2008-08-21 Fibrogen Inc Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
AU2006223131A1 (en) * 2005-03-11 2006-09-21 Alcon, Inc. RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
WO2006102333A2 (en) * 2005-03-21 2006-09-28 Alcon Manufacturing, Ltd. Ophthalmic use of agents which inhibit connective tissue growth factor binding and signalling via the trka/p75ntr receptor complex
CA2606778A1 (en) 2005-05-05 2006-11-16 Fibrogen, Inc. Vascular disease therapies
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP5602365B2 (ja) * 2005-10-25 2014-10-08 ザ・ジョンズ・ホプキンス・ユニバーシティ マルファン症候群及び関連疾患を治療するための方法及び組成物。
US20080070855A1 (en) * 2006-09-20 2008-03-20 James Pitzer Gills Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes
JP2011500024A (ja) 2007-10-12 2011-01-06 アドバンスド セル テクノロジー， インコーポレイテッド Ｒｐｅ細胞を生成する改良された方法およびｒｐｅ細胞の組成物
EP3081648A1 (de) * 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US8771692B2 (en) * 2009-07-02 2014-07-08 Fibrogen, Inc. Methods for treatment of muscular dystrophy
KR20120102709A (ko) 2009-11-17 2012-09-18 어드밴스드 셀 테크놀로지, 인코포레이티드 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
KR101063524B1 (ko) 2010-02-08 2011-09-07 한림대학교 산학협력단 검정옥수수 추출물을 함유하는 당뇨합병성 신장섬유증 억제용 조성물
WO2011119887A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP2550001B1 (de) 2010-03-24 2019-05-22 Phio Pharmaceuticals Corp. Rna-interferenz bei augenerkrankungen
CA2795270C (en) * 2010-04-13 2021-06-08 M-Lab Ag Diagnostic methods for glaucoma
SI2670411T1 (sl) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Protismiselne spojine, ki so usmerjene na rastni faktor veznega tkiva (CTGF), za uporabo v postopku zdravljenja keloidov ali hipertrofnih brazgotin
JP6106883B2 (ja) * 2012-08-27 2017-04-05 学校法人福岡大学 第二次高調波光を用いた新規コラーゲン線維化評価モデル
US11279934B2 (en) 2014-04-28 2022-03-22 Phio Pharmaceuticals Corp. Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
CA2947619A1 (en) * 2014-05-01 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
CN104745587B (zh) * 2015-01-05 2017-07-21 西安交通大学医学院第一附属医院 用于识别结缔组织生长因子的核酸适配子及其应用
TWI640308B (zh) * 2017-03-29 2018-11-11 林伯剛 Device for stimulating optic nerve fibers
TWI674124B (zh) * 2017-09-30 2019-10-11 三凡生技研發股份有限公司 促進眼睛保健之胜肽及其組合物
CN109706238B (zh) 2017-10-26 2023-04-07 珠海岐微生物科技有限公司 一种老年性黄斑病变的检测与治疗方法
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
KR102667208B1 (ko) 2018-11-14 2024-05-20 스마일바이오텍 주하이 리미티드 안구 내 질환 또는 병증에 대한 동물 모델, 스크리닝 방법 및 치료 방법
MX2022015327A (es) * 2020-06-05 2023-02-22 Occurx Pty Ltd Compuestos y metodos para el tratamiento de trastornos oculares.
WO2023196555A1 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for ocular fibrosis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US7026299B2 (en) * 1994-07-12 2006-04-11 Human Genome Sciences, Inc. Connective tissue growth factor-2
JPH11180895A (ja) * 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
DK1064382T3 (da) * 1998-03-17 2008-12-08 Genentech Inc Homologe polypeptider til VEGF og BMP1
PT1140969E (pt) * 1998-12-14 2007-08-30 Univ Miami Fragmentos do factor de crescimento de tecido conectivo e os seus métodos e utilizações
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF
AU2001276934A1 (en) * 2000-07-18 2002-02-05 Joslin Diabetes Center Inc. Methods of modulating fibrosis
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor

Also Published As

Publication number Publication date
JP2005519881A (ja) 2005-07-07
HK1069767A1 (en) 2005-06-03
EP1463531A1 (de) 2004-10-06
US20030153524A1 (en) 2003-08-14
EP1463531A4 (de) 2005-09-07
EP1463531B1 (de) 2011-09-28
WO2003049773A1 (en) 2003-06-19
CN1602207A (zh) 2005-03-30
AU2002366641A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
WO2003055443A3 (en) Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE435012T1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE424560T1 (de) Marker für neuromyelitis optica
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
DE602004010267D1 (de) Zusammensetzung mit mindestens einem substituiertem 2- 2-(4-aminophenyl)ethenyl -1-pyridinium-derivat, verfahren zur behandlung von keratinfasern damit, vorrichtung und verwendung
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
ATE371453T1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
ATE347698T1 (de) Verfahren zum nachweis von alzheimer-krankheit
WO2004083241A3 (en) Btc-interacting proteins and use thereof
ATE465408T1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
WO2006042137A3 (en) Methods for identifying parkinson's disease therapeutics
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
WO2007047634A3 (en) Method to diagnose, predict treatment response and develop treatments for psychiatric disorders using markers
DE69930725D1 (de) Verfahren und kits zur behandlung von vulvovaginalen candidosen mit mikonazolnitrat
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties